Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$63.74 USD
+1.37 (2.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
EW 63.74 +1.37(2.20%)
Will EW be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EW
Edwards Lifesciences (EW) Reliance on International Sales: What Investors Need to Know
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Edwards Lifesciences (EW) Q2 Earnings Match Estimates
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
Other News for EW
3 Healthcare Stocks to Buy at a 52-Week Low in July
Edwards Lifesciences just upgraded at Wolfe Research, here's why
Wall Street Breakfast: What Moved Markets
Hold Rating on Edwards Lifesciences Amid TAVR Challenges and Competitive Pressures
Market Whales and Their Recent Bets on Edwards Lifesciences Options